[A case of panuveitis with optic disc neovascularization associated with juvenile idiopathic arthritis which progressed during a clinical trial of etanercept].

Abstract

PURPOSE:

To report a case of uveitis associated with juvenile idiopathic arthritis that progressed from iritis to panuveitis with disc neovascularization during a clinical trial of etanercept, a tumor necrosis factor a (TNF-alpha) blocker.

CASE:

A 12-year-old girl with juvenile idiopathic arthritis, which had begun at the age of 1 year 7 months. The patient was enrolled in a clinical trial of etanercept at 11 years of age. The methotrexate which she has been taking was stopped, and prednisolone was decreased gradually from 7 mg. The iritis worsened and progressed to panuveitis with disc neovascularization when the prednisolone dose had been tapered to 2 mg. The uveitis was controlled by treatment with a steroid pulse and a liposteroid.

CONCLUSION:

When starting etanercept therapy in a patient with juvenile idiopathic arthritis who has uveitis and the antirheumatic drug is stopped and steroid treatment tapered, special care is needed to avoid the exacerbation of uveitis.

• Authors: Reiko Kinouchi, Hiroyuki Hirokawa, Shou Igarashi, Katsuhiko Fukui, Yoshiki Hirano, Yoshiko Takai, Akitoshi Yoshida
• Journal: Nippon Ganka Gakkai zasshi (Nippon Ganka Gakkai Zasshi) Vol. 111 Issue 12 Pg. 970-5 (Dec 2007) ISSN: 0029-0203 [Print] Japan
• PMID: 18186220 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Antirheumatic Agents
• Immunoglobulin G
• Receptors, Tumor Necrosis Factor
• Etanercept

Topics

• Antirheumatic Agents (adverse effects)
• Arthritis, Juvenile (drug therapy)
• Child
• Clinical Trials as Topic
• Etanercept
• Female
• Humans
• Immunoglobulin G (adverse effects)
• Neovascularization, Pathologic
• Optic Disk (pathology)
• Panuveitis (pathology)
• Receptors, Tumor Necrosis Factor